Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 157K | 28K | 0 | 0 | 20K |
| Gross Profit | 49K | 12K | 0 | 0 | 20K |
| Operating Income | -13M | -7M | -9M | -9M | -9M |
| EBITDA | -13M | -7M | -9M | -9M | -550K |
| Net Income | -13M | -8M | -9M | -9M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.69
+0.00% today
1Y Change
-74.19%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ZIVO Bioscience, Inc. (ZIVO) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $3.69 and down 74.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +468.6%, EPS growth of +14.8%, a dividend yield of 0.0%. What stands out right now is revenue +468.6%, EPS +14.8%, free cash flow +25.6% with operating margin -4045.7% and ROIC 342.8%. Valuation already assumes a fairly strong business story at price/sales 66.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZIVO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZIVO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZIVO Max Drawdown
-93.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZIVO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$20.0K
FY Net Income
-$9.7M
-2.8% YoY
Free Cash Flow
-$2.6M
+62.0% YoY
Revenue Growth
+468.6%
EPS Growth
+14.8%
Gross Margin
31.7%
Net Margin
-4059.7%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 157K | 28K | 0 | 0 | 20K |
| Gross Profit | 49K | 12K | 0 | 0 | 20K |
| Operating Income | -13M | -7M | -9M | -9M | -9M |
| EBITDA | -13M | -7M | -9M | -9M | -550K |
| Net Income | -13M | -8M | -9M | -9M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 274K | 2M | 9M | 138K |
| Total Assets | 2M | 556K | 2M | 9M | 220K |
| Total Liabilities | 2M | 3M | 2M | 3M | 12M |
| Shareholder Equity | -515K | -2M | -11K | 6M | -11M |
| Total Debt | 254K | 346K | 445K | 255K | 5M |
| Net Debt | -1M | 72K | -1M | -9M | 5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+62.0% YoY
Capital Expenditures
0
Free Cash Flow
3M
+62.0% YoY
Key ratios
Gross Margin
31.7%
Operating Margin
-4045.7%
Net Margin
-4059.7%
ROE
426.5%
Debt / Equity
-0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.